DANIEL MAYNE — Lobbyist Profile | Poliscope

DANIEL MAYNE

Filings

Clients

Firms

Years active

2026–2026

Associated filing income

—

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
BIOMARIN PHARMACEUTICAL INC.	4	2026

Lobbying firms

Firm	Filings	Years
BIOMARIN PHARMACEUTICAL INC.	4	2026

Bills explicitly cited in this lobbyist’s assigned issues (3)

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

H.R. 10359

Priority for Pediatric Cures Act

Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text

H.R.10359: PRIORITY FOR PEDIATRIC CURES ACT; PROVISIONS RELATED TO REMOVAL OF RARE PEDIATRIC PRIORITY REVIEW VOUCHERS SUNSET GENERAL DISCUSSIONS REGARDING CLINICAL TRIALS

H.R. 10571

Surge to Save Newborns Act

Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.

Open original LDA filing ↗

Cited source text

H.R.10571: SURGE TO SAVE NEWBORNS ACT; PROVISIONS RELATED TO NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING

Original LDA source filings (4)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.

2026 · third_quarter · Q3

Firm income: —Client expense: $200,000Open original LDA filing ↗

Assigned issues and filing targets (6 issues)

MMM

Medicare/Medicaid

GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT

HCR

Health Issues

H.R.10571: SURGE TO SAVE NEWBORNS ACT; PROVISIONS RELATED TO NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING

MED

Source: Senate LDA